97 related articles for article (PubMed ID: 15127232)
21. Sequence effect of docetaxel and carboplatin on toxicity, tumor response and pharmacokinetics in non-small-cell lung cancer patients: a phase I study of two sequences.
Ando M; Saka H; Ando Y; Minami H; Kuzuya T; Yamamoto M; Watanabe A; Sakai S; Shimokata K; Hasegawa Y
Cancer Chemother Pharmacol; 2005 Jun; 55(6):552-8. PubMed ID: 15856233
[TBL] [Abstract][Full Text] [Related]
22. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics.
Morgan RJ; Doroshow JH; Synold T; Lim D; Shibata S; Margolin K; Schwarz R; Leong L; Somlo G; Twardowski P; Yen Y; Chow W; Lin P; Paz B; Chu D; Frankel P; Stalter S
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5896-901. PubMed ID: 14676112
[TBL] [Abstract][Full Text] [Related]
23. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.
Kwon JH; Kim JH; Lee JA; Shin HC; Kim HJ; Song HH; Jung JY; Kim HY; Choi DR; Kim HS; Park YI; Zang DY
Cancer Chemother Pharmacol; 2010 Oct; 66(5):889-97. PubMed ID: 20091311
[TBL] [Abstract][Full Text] [Related]
24. Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial.
Georgoulias V; Ardavanis A; Agelidou A; Agelidou M; Chandrinos V; Tsaroucha E; Toumbis M; Kouroussis C; Syrigos K; Polyzos A; Samaras N; Papakotoulas P; Christofilakis C; Ziras N; Alegakis A
J Clin Oncol; 2004 Jul; 22(13):2602-9. PubMed ID: 15226327
[TBL] [Abstract][Full Text] [Related]
25. A phase II study of induction chemotherapy followed by concurrent chemoradiotherapy in elderly patients with locally advanced non-small-cell lung cancer.
Giorgio CG; Pappalardo A; Russo A; Santini D; Di Rosa C; Di Salvo C; Castorina S; Marletta F; Bellissima G; Palermo N; Scuderi C; Bordonaro R
Anticancer Drugs; 2007 Jul; 18(6):713-9. PubMed ID: 17762402
[TBL] [Abstract][Full Text] [Related]
26. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
Langer CJ; Millenson M; O'Dwyer P; Kosierowski R; Alexander R; Litwin S; McAleer CA; Bonjo CA; Ozols R
Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119
[TBL] [Abstract][Full Text] [Related]
27. Relationship of systemic exposure to unbound docetaxel and neutropenia.
Baker SD; Li J; ten Tije AJ; Figg WD; Graveland W; Verweij J; Sparreboom A
Clin Pharmacol Ther; 2005 Jan; 77(1):43-53. PubMed ID: 15637530
[TBL] [Abstract][Full Text] [Related]
28. Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Johnson S; Ozols RF
Semin Oncol; 1995 Aug; 22(4 Suppl 9):18-29. PubMed ID: 7544025
[TBL] [Abstract][Full Text] [Related]
29. A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer.
Kouroussis C; Agelaki S; Mavroudis D; Kakolyris S; Androulakis N; Kalbakis K; Souglakos J; Mallas K; Bozionelou V; Pallis A; Adamtziki H; Georgoulias V
Anticancer Res; 2003; 23(1B):785-91. PubMed ID: 12680184
[TBL] [Abstract][Full Text] [Related]
30. Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly.
ten Tije AJ; Verweij J; Carducci MA; Graveland W; Rogers T; Pronk T; Verbruggen MP; Dawkins F; Baker SD
J Clin Oncol; 2005 Feb; 23(6):1070-7. PubMed ID: 15718305
[TBL] [Abstract][Full Text] [Related]
31. Combination of nedaplatin and vindesine for treatment of relapsed or refractory non-small-cell lung cancer.
Takigawa N; Segawa Y; Ueoka H; Kiura K; Tabata M; Shibayama T; Takata I; Miyamoto H; Eguchi K; Harada M
Cancer Chemother Pharmacol; 2000; 46(4):272-8. PubMed ID: 11052624
[TBL] [Abstract][Full Text] [Related]
32. A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors.
Witta SE; Gustafson DL; Pierson AS; Menter A; Holden SN; Basche M; Persky M; O'Bryant CL; Zeng C; Baron A; Long ME; Gibbs A; Kelly K; Bunn PA; Chan DC; Pallansch P; Eckhardt SG
Clin Cancer Res; 2004 Nov; 10(21):7229-37. PubMed ID: 15534096
[TBL] [Abstract][Full Text] [Related]
33. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients.
Nygren P; Hande K; Petty KJ; Fedgchin M; van Dyck K; Majumdar A; Panebianco D; de Smet M; Ahmed T; Murphy MG; Gottesdiener KM; Cocquyt V; van Belle S
Cancer Chemother Pharmacol; 2005 Jun; 55(6):609-16. PubMed ID: 15723220
[TBL] [Abstract][Full Text] [Related]
34. Docetaxel administration schedule: from fever to tears? A review of randomised studies.
Engels FK; Verweij J
Eur J Cancer; 2005 May; 41(8):1117-26. PubMed ID: 15911234
[TBL] [Abstract][Full Text] [Related]
35. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.
Bruno R; Hille D; Riva A; Vivier N; ten Bokkel Huinnink WW; van Oosterom AT; Kaye SB; Verweij J; Fossella FV; Valero V; Rigas JR; Seidman AD; Chevallier B; Fumoleau P; Burris HA; Ravdin PM; Sheiner LB
J Clin Oncol; 1998 Jan; 16(1):187-96. PubMed ID: 9440742
[TBL] [Abstract][Full Text] [Related]
36. Open-label, randomized, single-dose, crossover study to evaluate the pharmacokinetics and safety differences between two docetaxel products, CKD-810 and Taxotere injection, in patients with advanced solid cancer.
Cho EK; Park JY; Lee KH; Song HS; Min YJ; Kim YH; Kang JH
Cancer Chemother Pharmacol; 2014 Jan; 73(1):9-16. PubMed ID: 24337589
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and toxicity of weekly docetaxel in older patients.
Hurria A; Fleming MT; Baker SD; Kelly WK; Cutchall K; Panageas K; Caravelli J; Yeung H; Kris MG; Gomez J; Miller VA; D'Andrea G; Scher HI; Norton L; Hudis C
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6100-5. PubMed ID: 17062686
[TBL] [Abstract][Full Text] [Related]
38. Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer.
Tamiya A; Naito T; Miura S; Morii S; Tsuya A; Nakamura Y; Kaira K; Murakami H; Takahashi T; Yamamoto N; Endo M
Anticancer Res; 2012 Mar; 32(3):1103-6. PubMed ID: 22399640
[TBL] [Abstract][Full Text] [Related]
39. Docetaxel in the treatment of non-small cell lung cancer (NSCLC) -- an observational study focusing on symptom improvement.
Pircher A; Wasle IK; Mian M; Gamerith G; Ulsperger E; Studnicka M; Mohn-Staudner A; Hilbe W; Fiegl M
Anticancer Res; 2013 Sep; 33(9):3831-6. PubMed ID: 24023316
[TBL] [Abstract][Full Text] [Related]
40. Potential for improvement of docetaxel-based chemotherapy: a pharmacological review.
Engels FK; Sparreboom A; Mathot RA; Verweij J
Br J Cancer; 2005 Jul; 93(2):173-7. PubMed ID: 16012521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
